Umoja Biopharma, Inc. – Trademark Portfolio
Entity Type: 03
Umoja Biopharma, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 2 trademarks are registered and 4 are pending. Notable registered marks include U and UMOJA. The owner is based in Seattle, WA.
1150 Eastlake Ave E, Suite 400
Seattle, WA 98109
Showing of trademarks Trademarks
Trademark Classifications
Umoja Biopharma, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Umoja Biopharma, Inc. have?
Umoja Biopharma, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 pending.
What trademark classes does Umoja Biopharma, Inc. file in?
Umoja Biopharma, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Umoja Biopharma, Inc.'s most well-known trademarks?
Umoja Biopharma, Inc.'s registered trademark portfolio includes well-known marks such as U and UMOJA. These are among 2 currently registered trademarks in the portfolio.
What is Umoja Biopharma, Inc.'s trademark registration success rate?
Umoja Biopharma, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 4 applications are pending review.